The Competitive Future of Polycythemia Vera Management in 2025

added article Health

2025-11-09 11:22:38 -

The treatment landscape for polycythemia vera is undergoing significant changes as older therapies face patent expiration and newer biologics gain traction. JAKAFI (ruxolitinib) has been the leading treatment for patients resistant or intolerant to hydroxyurea. However, the anticipated arrival of generic ruxolitinib may be delayed, prolonging its market dominance and maintaining high costs for...

0 Comments 0 Shares 97 Views